Overview

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this study is to examine the safety, tolerability, pharmacokinetics (how the body processes a drug), and activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Non-Alcoholic Steatohepatitis (also known as NASH).
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences